Estrogen News and Research

Latest Estrogen News and Research

3-D structure of proteins show flame retardants can mimic estrogen hormones

By determining the three-dimensional structure of proteins at the atomic level, researchers at the National Institutes of Health have discovered how some commonly used flame retardants, called brominated flame retardants (BFRs), can mimic estrogen hormones and possibly disrupt the body's endocrine system. BFRs are chemicals added or applied to materials to slow or prevent the start or growth of fire.

20 Aug 2013

Hypnotic relaxation therapy improves sexual health in postmenopausal women

Hypnotic relaxation therapy improves sexual health in postmenopausal women who have moderate to severe hot flashes, according to Baylor University researchers who presented their findings at the American Psychological Association's recent annual meeting.

16 Aug 2013

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Osteoarthritis is an extremely common condition affecting about 8 million people in the UK. The elderly are particularly susceptible, with up to 45% of people over 65 years, having the disease.

14 Aug 2013

Women diagnosed for menopause after breast cancer may vary with type of doctors

Hormonal treatment for breast cancer causes menopause in over 80% of women in the first year of therapy, but now new research, published in the peer-reviewed journal Climacteric, has found that how these women are diagnosed and treated for menopausal symptoms can vary substantially according to which type of doctor a woman sees.

13 Aug 2013

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells to inhibit proliferation. According to BreastCancer.org 1 in 8 women in the U.S. will develop invasive breast cancer and more than 39,000 deaths occur annually.

12 Aug 2013

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Cancer drugs known as ErbB inhibitors have shown great success in treating many patients with lung, breast, colon and other types of cancer. However, ErbB drug resistance means that many other patients do not respond, and even among those who do, tumors commonly come back.

7 Aug 2013

Atossa Genetics: Many American women still not aware of breast cancer risk

Virtually all American women are aware that the pink ribbon is the symbol of breast cancer awareness. Despite this near-universal recognition, it is still a sad fact that plenty of women do not truly appreciate the extent to which they are at risk for breast cancer.

3 Aug 2013

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.

2 Aug 2013

Study reveals that black women with breast cancer continue to have lower survival rate

In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Discovery may help explain how anti-inflammatory steroid drugs work

A gene long presumed dead comes to life under the full moon of inflammation, Stanford University School of Medicine scientists have found.

23 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

Cancer survivors twice as likely to experience severe menopausal symptoms

Cancer survivors were twice as likely to experience severe menopausal symptoms compared to women who have not had cancer, a new Australian study has found.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Modified forms of bisphenol A found to alter hormone signaling in new, disturbing ways

For years, scientists have been worried about bisphenol A. The chemical is known as an "endocrine disruptor," a substance that interferes with the body's hormone signaling system, and it's found in everything from plastic drink bottles to the linings of food and drink cans to the thermal paper used for cash register receipts - not to mention the urine of 92.6 percent of Americans over the age of six.

18 Jul 2013

Study shows flavonoid-based nutritional supplements can affect endocrine system

Plant-based diets are healthy. Plants are high in flavonoids. So flavonoids are healthy. At least that's the reasoning of many manufacturers of flavonoid-based nutritional supplements.

16 Jul 2013

Scientists discover how BRCA1 gene mutations predispose women to breast and ovarian cancers

Scientists led by Drs. Mona Gauthier and Tak Mak at The Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre have solved a key piece in the puzzle of how BRCA1 gene mutations specifically predispose women to breast and ovarian cancers.

16 Jul 2013

Researchers identify receptor mutation that blocked estrogen action in young woman

A receptor mutation that essentially blocks estrogen's action has been identified for the first time a female, researchers report.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Multiple pregnancies conceived after IVF associated with increased breast cancer risk

Women who give birth to multiple babies following IVF treatment are at a higher risk of breast cancer than those giving birth to singletons or who remain childless. Dutch investigators from the Omega study group said the explanation may not be the multiple pregnancy per se but a maternal trait related to a higher implantation potential and to breast cancer itself.

9 Jul 2013

Estrogen News and Research

Latest Estrogen News and Research

3-D structure of proteins show flame retardants can mimic estrogen hormones

Hypnotic relaxation therapy improves sexual health in postmenopausal women

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Women diagnosed for menopause after breast cancer may vary with type of doctors

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Atossa Genetics: Many American women still not aware of breast cancer risk

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

Study reveals that black women with breast cancer continue to have lower survival rate

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Discovery may help explain how anti-inflammatory steroid drugs work

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Cancer survivors twice as likely to experience severe menopausal symptoms

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Modified forms of bisphenol A found to alter hormone signaling in new, disturbing ways

Study shows flavonoid-based nutritional supplements can affect endocrine system

Scientists discover how BRCA1 gene mutations predispose women to breast and ovarian cancers

Researchers identify receptor mutation that blocked estrogen action in young woman

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Multiple pregnancies conceived after IVF associated with increased breast cancer risk

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Estrogen News and Research

Latest Estrogen News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in